A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Revolution Medicines, Inc.
Centre hospitalier de l'Université de Montréal (CHUM)
GlaxoSmithKline
Eli Lilly and Company
Accent Therapeutics
A2 Biotherapeutics Inc.
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Revolution Medicines, Inc.
University of Colorado, Denver
GlaxoSmithKline
University of Nebraska
Natera, Inc.
Novartis
Institut du Cancer de Montpellier - Val d'Aurelle
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Sahlgrenska University Hospital
Elicio Therapeutics
Institut Bergonié
Guardant Health, Inc.
University of California, San Francisco
ModeX Therapeutics, An OPKO Health Company
Tempus AI
Esperas Pharma Inc.
Stanford University
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Universitat Jaume I
Stanford University
Taproot Health
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
DxTerity Diagnostics
UTC Therapeutics Inc.
Jules Bordet Institute
University of Aarhus
Assiut University
Dublin City University
Institut de cancérologie Strasbourg Europe
Charite University, Berlin, Germany
Corvus Pharmaceuticals, Inc.
Charite University, Berlin, Germany
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Klus Pharma Inc.
St Vincent's University Hospital, Ireland